Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Three therapies, Teva’s Huntexil, Auspex’s SD-809 and Raptor’s Procysbi, will likely receive regulatory approval for Huntington’s disease in the United States and the EU5 markets... Learn More
Join us live on September 10, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
Come join us for an exciting one-day seminar.
Hear in-depth analysis of hot topics and trends concerning global oncology while engaging directly with Decision Resources Group analysts.
View the Agenda | Meet our expert speakers
August 27, 2014
Population Health Management Will Expand to More Type 2 Diabetes Patients
August 21, 2014
Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify
Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms
August 20, 2014
Payers Exert Cost Controls on High-Cost Biologics to Treat Autoimmune Conditions
Immunotherapy Drug Combinations: Partnering in Immuno-Oncology
Partnership deals in immunotherapy are forming rapidly as key players identify combination treatments as the big second... Read More
Muscular dystrophy (MD) is associated with degeneration and weakness of affected muscles that vary with the type of... Read More
Consumer Digital Marketing in the United States: The Digital Health Journey and Opportunities for Pharma Marketers
The emergence of digital resources in the healthcare system has changed the healthcare experience for U.S.... Read More